Anti-NGF antibody
Description
Application Data
Description
-
Antibody raised against NGF, a neuropeptide used in development, maintenance and survival of nerve cells, particularly sympathetic and sensory neurons. In the absence of NGF these cells undergo apoptosis.
Application Data
-
Material Safety Data Sheet (MSDS)Catalogue number crb2005667 Antibody Anti-NGF antibody Antigen Peptide KLH conjugated synthetic peptide crb1200876e Protein ID P01138 NGF Aliases Beta-nerve growth factor, Beta-NGF Host Species Rabbit Antibody Type Polyclonal Concentration 4.0mg/ml Glycine (R2G), 3.0mg/ml Glycine (R1G) Target NGF Storage Stabilisers The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. Family NGF-beta family Storage The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. References Hirose, M., Kuroda, Y. and Murata, E. (2015). NGF/TrkA Signaling as a Therapeutic Target for Pain. Pain Practice, 16(2), pp.175–182.
Johnson, D., et al. (1986). Expression and structure of the human NGF receptor. Cell, 47(4), pp.545–554.
Stoleru, B., et al. (2013). Tropomyosin-Receptor-Kinases Signaling in the Nervous System. Mædica, 8(1), pp.43–48.
Nerve growth factor (NGF) is a neurotrophic factor and neuropeptide involved in the regulation of specific neurons through control of neuronal growth, maintenance, proliferation, and survival. NGF protein functions as the extracellular ligand for the NTRK1 or the NGFR receptors on the surface of neurons, initiating signalling cascades inside the cell. Binding of NGF causes neurons to mature and differentiate; additionally, NGF is critical in the survival of sympathetic and sensory neurons, as in the absence of NGF these cells will undergo apoptosis.
NGF is capable of binding with two classes of receptors, both tropomyosin receptor kinase A (TrkA) and low-affinity NGF receptor (LNGFR) act as ligands for NGF, activating signalling cascades. These receptors are associated with neurodegenerative diseases, implying the potential of NGF as a therapeutic drug target.